8 August 2017 in Journal of Diabetes Investigation
Aims/Introduction: Diabetic nephropathy is one of the leading causes of end‐stage renal disease. Unfortunately, reliable surrogate markers for predicting the prognostic outcome of diabetic nephropathy are as yet absent. In order to find new markers in predicting the progression of diabetic nephropathy, we carried out a prospective study by investigating the correlation between serum metabolites and the annual change of estimated glomerular filtration rate (eGFR).Materials and Methods: From September 2013 to September 2015, 52 diabetes patients at various stages of chronic kidney disease were enrolled. While serum levels of 175 metabolites were measured by AbsoluteIDQ™ p180 kit, only those with a significant difference in advancing chronic kidney disease stages were selected. After then, serial renal function change of these patients was followed up for 12 months, the outcome of renal function with each selected metabolite was compared according to the occurrence of a rapid decline (sustained annual decrement rate ≥5%) of eGFR.Results: A total of 26 metabolites were found to be significantly associated with the severity of chronic kidney disease. Tryptophan (Trp) showed a significant association with the event of rapid decline in eGFR (P = 0.036). Serum concentration of Trp <44.20 μmol/L showed the most valuable predictive value with 55.6% sensitivity and 87% specificity.Conclusions: A lower level of Trp, especially <44.20 μmol/L, was related to a rapid decline in eGFR. Accordingly, Trp might be regarded as a potential prognostic marker for diabetic nephropathy.
7 June 2020 in Journal of Diabetes Investigation
Aims/Introduction: Obesity and metabolic syndrome are well‐known to be associated with multiple chronic diseases. Currently, high‐dose liraglutide has been used for weight control in non‐diabetic patients. Considering incretin‐based therapy is more effective in Asian populations, the effect of low‐dose liraglutide in weight control among these non‐diabetic groups has not been well evaluated. Our study aimed to evaluate the efficacy of low‐dose liraglutide in weight control among Taiwan patients.Materials and Methods: From July 2017 to December 2018, 46 non‐diabetic patients with metabolic syndrome were included. They had received low‐dose liraglutide at 0.6 or 1.2 mg per day for weight reduction for 12 weeks. After then, changes in bodyweight, waist and metabolic factors were examined. Overt bodyweight reduction was defined as a decrease of >5% within 12 weeks.Results: With 12 weeks of medication use, both groups showed statistical weight reduction. Higher doses of liraglutide had better efficacy, and 44.4% of patients in the liraglutide 1.2 mg group reached overt weight reduction, whereas just 32.1% in the 0.6 mg group had achieved this. Young age was found to be a predictor factor for a positive finding (odds ratio 0.941, P = 0.037). Early responders with decreased bodyweight of >4.2% within the first 4 weeks indicated a better chance to achieve measurable weight reduction.Conclusions: Low‐dose liraglutide still has high efficacy in weight reduction in Taiwanese people, especially for those of younger age.